Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Larimar Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Larimar Therapeutics, Inc.

LRMR

Larimar Therapeutics, Inc.

About Larimar Therapeutics, Inc.

Larimar Therapeutics is a biotech company developing treatments for rare genetic diseases using its proprietary cell-penetrating peptide platform. Its lead candidate, nomlabofusp, aims to increase mitochondrial frataxin levels in Friedreich’s ataxia patients. The company focuses on clinical development, regulatory approval, and leveraging its technology for other intracellular protein deficiencies, targeting underserved markets with innovative protein delivery therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Larimar Therapeutics, Inc.

1
1
Larimar Therapeutics, Inc. Larimar Therapeutics Reports Q1 2026 Financial Results with $29.6M Net Loss

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
Larimar Therapeutics, Inc. Larimar Therapeutics Reports $165.7 Million Net Loss and Advances Nomlabofusp Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Larimar Therapeutics, Inc. Larimar Therapeutics Reports $47.7 Million Net Loss in Q3 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Larimar Therapeutics, Inc. Larimar Therapeutics Reports $26.2 Million Net Loss in Q2 2025, Plans BLA Submission for Nomlabofusp

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Larimar Therapeutics, Inc. Larimar Therapeutics Reports $29.3 Million Net Loss in Q1 2025, Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Larimar Therapeutics, Inc. Larimar Therapeutics Reports $80.6 Million Net Loss and Advances Clinical Trials for Nomlabofusp

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Larimar Therapeutics, Inc. Larimar Therapeutics Reports Financial Developments, Increased Cash Reserves, and Progress in Clinical Programs

Via official filing (AI summary) | over 1 year ago | 0 comments